MaxCyte, Inc.

MaxCyte, a leading provider of cell-engineering platform technologies, enabling next‐gen cell-based therapies to improve lives.

[MaxCyte, Inc. @MaxCyte_info]

Are you ready?

Take the leap on February 23.

[MaxCyte, Inc. @MaxCyte_info]

We’re heading to the CRISPR Medicine Summit in Boston (23–24 Mar). Looking forward to discussions on therapeutic gene editing, delivery strategies, and clinical translation.

#CRISPR #GeneEditing

[MaxCyte, Inc. @MaxCyte_info]

We’re heading to CAR-TCR Summit Europe in London (24–26 Feb).

Stop by Booth 12 to connect with Alicia Roig-Merino, Ben Cavagan, and Dawar Pasha and discuss next-gen CAR/TCR innovation and scalable manufacturing strategies.

#CARTCR #CellTherapy

[MaxCyte, Inc. @MaxCyte_info]

Electroporation is now foundational to immunotherapy—but how do you use it effectively?

This eBook covers the basics of electroporation for T cell and NK cell engineering, from non-viral delivery to scalable workflows.

🔗 https://t.co/ECXAsgHupz

[MaxCyte, Inc. @MaxCyte_info]

From the floor at CGT Manufacturing DACH in Basel.

Great discussions on scalable CGT manufacturing, plus our lineup of plushie cells & molecules!

[MaxCyte, Inc. @MaxCyte_info]

We’ll be in Basel for CGT Manufacturing DACH 2026 (11–12 Feb). Looking forward to conversations on scalable CGT manufacturing. More info: https://t.co/q2znQ8eZdQ

[MaxCyte, Inc. @MaxCyte_info]

One month to Festival of Biologics USA in San Diego (4–5 Mar). Looking forward to conversations across biologics and CGT!
https://t.co/Hzztw2q2Sz

[MaxCyte, Inc. @MaxCyte_info]

We’re serious about cell engineering — and about having fun.

Team building was part of our recent General Sales Meeting, including a night at Dave & Buster’s. Congrats to the Red Team for winning the scavenger hunt—and to all for a great meeting. Energized for the year ahead!

[MaxCyte, Inc. @MaxCyte_info]

Looking forward to CAR-TCR Summit Europe!

📍 London, UK
📅 24–26 Feb 2026

An exciting forum for next-generation CAR and TCR innovation—spanning receptor and signaling design through to scaling, automation, and point-of-care strategies.

https://t.co/O1ZH0b7Hci

[MaxCyte, Inc. @MaxCyte_info]

We’re excited for the next stop on the 2026 G-Rex® Grant Tour: Philadelphia on Feb 19.

📍 The Franklin Institute
🕚 11 AM–9 PM

Stop by our table and say hello to Sarah Schuett.

👉 Register here: https://t.co/G2tglPTkVG

[MaxCyte, Inc. @MaxCyte_info]

Having a great time at ISGCT 2026 in Galway.

Fantastic conversations, familiar faces, new connections—and a small nod to the Emerald Isle if you look closely.

Be sure to visit us at booth 18 on day 2.

Sláinte!

#ISGCT2026 #CellGeneTherapy

[MaxCyte, Inc. @MaxCyte_info]

We’re excited to be going to Basel for Biologics / CGT Manufacturing DACH 2026 🇨🇭

📅 Feb 11–12 | 📍 Basel Marriott Hotel
🎯 Sponsor & exhibitor
📌 Poster: Accelerating Next-Gen Cell Therapy Manufacturing

Meet Amandine Girard & Miguel Jimenez
🔗 https://t.co/q2znQ8eZdQ

[MaxCyte, Inc. @MaxCyte_info]

One week to #ISGCT2026 in Galway.

We’ll be at Booth 18—stop by to meet Ben Cavagan (BD Manager) and Linda Meggiolaro (FAS). Looking forward to connecting with the cell & gene therapy community.

https://t.co/LO58XvB48L

[MaxCyte, Inc. @MaxCyte_info]

The 2026 G-Rex® Grant Tour, hosted by ScaleReady, kicks off in Houston on Jan 21.
📍 Texas Medical Center (TMC3)

Meet and hear from industry, academic & patient advocacy experts in CGT.

We’re excited to be there with a MaxCyte table on site.

👉 https://t.co/VsjuD01xO5

[MaxCyte, Inc. @MaxCyte_info]

This is what investing in your success upfront means:

Working with Kamau Therapeutics, we helped optimize and qualify a scalable, closed CMC process using our ExPERT platform, supporting advancement of nula-cel into the clinic for sickle cell disease: https://t.co/L9ug7EQdDa

[MaxCyte, Inc. @MaxCyte_info]

Two weeks until ISGCT 2026 in Galway.

We’re excited to be attending and connecting with the global cell & gene therapy community around the science, technologies, and collaborations shaping what’s next.

See you there!

#ISGCT2026 #CellGeneTherapy

[MaxCyte, Inc. @MaxCyte_info]

Happy New Year's 2026! We’re excited to work with you this year on continued growth and development in cell engineering and gene editing. Here we go!

[MaxCyte, Inc. @MaxCyte_info]

Want a quick refresher on MaxCyte workflows—and more case studies like this clip?

Earlier this year, we shared a quick 15-min overview of how high-efficiency electroporation supports cell engineering from discovery through manufacturing.

Watch on demand: https://t.co/tGKegO3dmr

[MaxCyte, Inc. @MaxCyte_info]

Happy holidays from all of us at MaxCyte. Wishing you a wonderful season and a strong start to the new year!

[MaxCyte, Inc. @MaxCyte_info]

Think of the Strategic Platform License as the next step to build momentum.

KSQ Tx & MaxCyte worked through editing, scalability, and TIL variability challenges together—building a GMP-ready process and clearing IND for KSQ-001EX.

KSQ case study → https://t.co/syUl5Ax4nq